A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments...

Area of Science:

• Clinical pharmacology
• Biostatistics
• Rare disease research

Background:

• Clinical trials for rare neurological diseases (RNDs) face challenges including limited data and small patient populations.
• Optimal trial design and analysis strategies are crucial for efficient RND drug development.

Purpose of the Study:

• To propose a pharmacometrics-informed clinical scenario evaluation framework (CSE-PMx) for optimizing clinical trial design and analysis in RNDs.
• To demonstrate the utility of CSE-PMx using an example in Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS).

Main Methods:

• Developed a CSE-PMx framework incorporating disease progression modeling, randomization methods, and randomization tests.
• Simulated individual longitudinal outcomes for clinical trial scenarios.
• Applied the framework to an exemplary trial for ARSACS, comparing treatment effects.

Main Results:

• Simulation evidence suggests a nonlinear mixed-effects model (NLMEM) with population-based likelihood ratio test analysis is robust and powerful for RND trials.
• The proposed NLMEM approach outperformed conventional methods like t-test, ANCOVA, and MMRM in the ARSACS example.
• The CSE-PMx framework demonstrated flexibility and generalizability for various rare disease indications.

Conclusions:

• The CSE-PMx framework provides a systematic approach to optimize clinical trial design and analysis for RNDs.
• Pharmacometrics-informed simulation and advanced statistical methods like NLMEM enhance the power and validity of RND clinical trials.
• This framework can accelerate the development of effective treatments for rare neurological diseases.